Peter C. Everett, MD

Assistant Professor, Medicine

Peter Everett
617.638.7526
818 Harrison Ave

Biography

Dr. Peter Everett is an Assistant Professor of Medicine at Chobanian and Avedisian School of Medicine (BUSM) and a medical oncologist in the Section of Hematology and Medical Oncology at Boston Medical Center (BMC). He received his undergraduate degree from Cornell University and his medical degree from Chobanian and Avedisian School of Medicine. Following that, he completed training in Internal Medicine and a fellowship in Hematology and Medical Oncology at Boston Medical Center, where he also served as the Chief Fellow. Dr. Everett specializes in head, neck and thoracic oncology.

Other Positions

  • Member, Evans Center for Interdisciplinary Biomedical Research, Boston University

Websites

Education

  • Boston University School of Medicine, MD
  • Cornell University, BS

Publications

  • Published on 6/8/2023

    Qureshi MM, Lin Y, Moeller AR, Yan SX, Dyer MA, Suzuki K, Everett P, Litle V, Truong MT, Mak KS. Change in stage after neoadjuvant chemoradiation is associated with survival in patients with esophageal cancer. J Surg Oncol. 2023 Oct; 128(5):781-789. PMID: 37288789.

    Read at: PubMed
  • Published on 8/1/2022

    Lee MH, Qureshi MM, Suzuki K, Everett P, Tapan U, Mak KS. Small cell lung cancer in young patients: trends in sociodemographic factors, diagnosis, treatment, and survival. J Thorac Dis. 2022 Aug; 14(8):2880-2893. PMID: 36071763.

    Read at: PubMed
  • Published on 10/19/2021

    Hanna GJ, O'Neill A, Shin KY, Wong K, Jo VY, Quinn CT, Cutler JM, Flynn M, Lizotte PH, Annino DJ, Goguen LA, Kass JI, Rettig EM, Sethi RKV, Lorch JH, Schoenfeld JD, Margalit DN, Tishler RB, Everett PC, Desai AM, Cavanaugh ME, Paweletz CP, Egloff AM, Uppaluri R, Haddad RI. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 02 01; 28(3):468-478. PMID: 34667025.

    Read at: PubMed
  • Published on 8/3/2021

    Freydman J, Henshaw L, Patel JV, Smith CE, Everett PC. Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC. Ann Pharmacother. 2022 04; 56(4):503-504. PMID: 34344199.

    Read at: PubMed
  • Published on 10/20/2020

    Tapan U, Furtado VF, Qureshi MM, Everett P, Suzuki K, Mak KS. Racial and Other Healthcare Disparities in Patients With Extensive-Stage SCLC. JTO Clin Res Rep. 2021 Jan; 2(1):100109. PMID: 34589974.

    Read at: PubMed
  • Published on 1/9/2019

    Shah NK, Qureshi MM, Dyer MA, Patel SA, Kim K, Everett PC, Grillone GA, Jalisi SM, Truong MT. Optimal sequencing of chemoradiotherapy for locally advanced laryngeal cancer. Laryngoscope. 2019 10; 129(10):2313-2320. PMID: 30628077.

    Read at: PubMed
  • Published on 2/8/2018

    Kirke DN, Qureshi MM, Kamran SC, Ezzat W, Jalisi S, Salama A, Everett PC, Truong MT. Role of adjuvant chemoradiotherapy in T4N0 stage IV head and neck cancer: A National Cancer Database analysis. Head Neck. 2018 06; 40(6):1174-1184. PMID: 29417687.

    Read at: PubMed
  • Published on 4/25/2012

    Tan JN, Kroll MH, O'Hara CJ, Everett PC, Erdogan E. Gamma heavy chain disease in a patient with underlying lymphoplasmacytic lymphoma of the thyroid. Report of a case and comparison with other reported cases with thyroid involvement. Clin Chim Acta. 2012 Oct 9; 413(19-20):1696-9. PMID: 22561184.

    Read at: PubMed
  • Published on 9/2/2010

    Ren JG, Seth P, Everett P, Clish CB, Sukhatme VP. Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2. PLoS One. 2010 Sep 02; 5(9). PMID: 20824065.

    Read at: PubMed
  • Published on 1/1/2007

    Everett PC, Meyers JA, Makkinje A, Rabbi M, Lerner A. Preclinical assessment of curcumin as a potential therapy for B-CLL. Am J Hematol. 2007 Jan; 82(1):23-30. PMID: 16947318.

    Read at: PubMed

View 6 more publications: View full profile at BUMC

View all profiles